Skip to Content

View Additional Section Content

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/record/NCT02983799?cond=with+Different+HRD+Tumor+Status&rank=1

Clinical Trial Categories

  • Ovarian Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    Asplundh Cancer Pavilion
    3941 Commerce Ave
    Willow Grove, PA 19090
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM